Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The role of JAK inhibitors in multiple myeloma.

Ghermezi M, Spektor TM, Berenson JR.

Clin Adv Hematol Oncol. 2019 Sep;17(9):500-505.

PMID:
31549971
2.

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Udd KA, Bujarski S, Wirtschafter E, Spektor TM, Ghermezi M, Rassenti LZ, David ME, Nosrati JD, Rahbari AA, Wang J, Vardanyan S, Harutyunyan NM, Linesch J, Li M, Sanchez E, Chen H, Kipps TJ, Berenson JR.

Target Oncol. 2019 Oct;14(5):551-561. doi: 10.1007/s11523-019-00666-0.

PMID:
31473933
3.

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.

Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, Cao J, Hekmati T, Zahab B, Nosrati JD, Wen M, Wang CS, Tang G, Xu N, Spektor TM, Berenson JR.

Br J Haematol. 2019 Aug 18. doi: 10.1111/bjh.16158. [Epub ahead of print]

PMID:
31423579
4.

Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.

Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, Patil S, Udd K, Bujarski S, Cao J, Hekmati T, Ghermezi M, Zhou M, Wang EY, Tanenbaum EJ, Zahab B, Schlossberg R, Yashar MA, Wang CS, Tang GY, Spektor TM, Berenson JR.

Leuk Res. 2019 Jun;81:62-66. doi: 10.1016/j.leukres.2019.04.008. Epub 2019 Apr 18.

PMID:
31035033
5.

Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.

Rahbari KJ, Nosrati JD, Spektor TM, Berenson JR.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18. No abstract available.

PMID:
30033209
6.

Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.

Gross Z, Rahbari A, Wirtschafter E, Spektor TM, Udd KA, Bujarski S, Ghermezi M, Nosrati JD, Vidisheva A, Eades B, Cecchi G, Maluso T, Swift R, Berenson JR.

Eur J Haematol. 2018 Jun;100(6):621-623. doi: 10.1111/ejh.13058. Epub 2018 Apr 25.

PMID:
29524348
7.

Monitoring multiple myeloma.

Udd KA, Spektor TM, Berenson JR.

Clin Adv Hematol Oncol. 2017 Dec;15(12):951-961.

PMID:
29315287
8.

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.

Cohen A, Spektor TM, Stampleman L, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Maluso T, Swift RA, Vescio R, Berenson JR.

Br J Haematol. 2018 Jan;180(1):60-70. doi: 10.1111/bjh.14992. Epub 2017 Nov 21.

PMID:
29164606
9.

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.

Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, Berenson JR.

Support Care Cancer. 2017 Oct;25(10):3217-3224. doi: 10.1007/s00520-017-3732-6. Epub 2017 Apr 28.

PMID:
28455546
10.

Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.

Chen H, Li M, Sanchez E, Wang CS, Lee T, Soof CM, Casas CE, Cao J, Xie C, Udd KA, DeCorso K, Tang GY, Spektor TM, Berenson JR.

Mol Cancer Res. 2017 May;15(5):598-609. doi: 10.1158/1541-7786.MCR-16-0293. Epub 2017 Jan 25.

11.

Circulating proteasomes: circling myeloma with a new potential biomarker.

Spektor TM, Berenson JR.

Leuk Lymphoma. 2017 Mar;58(3):513-515. doi: 10.1080/10428194.2016.1274981. Epub 2017 Jan 16. No abstract available.

PMID:
28093000
12.

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.

Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, Spektor TM, Andreu-Vieyra C, Petraki S, Sanchez E, Udd K, Wang CS, Swift RA, Chen H, Berenson JR.

Haematologica. 2017 Apr;102(4):785-795. doi: 10.3324/haematol.2016.150896. Epub 2016 Dec 29.

13.

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR.

Ann Hematol. 2017 Mar;96(3):449-459. doi: 10.1007/s00277-016-2889-2. Epub 2016 Dec 8.

PMID:
27933373
14.

Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.

Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR.

Ann Hematol. 2017 Mar;96(3):441-448. doi: 10.1007/s00277-016-2888-3. Epub 2016 Dec 2.

PMID:
27913860
15.

Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.

Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, Ibrahim E, Treisman J, Masri M, Berenson JR.

Support Care Cancer. 2016 Jul;24(7):3105-10. doi: 10.1007/s00520-016-3126-1. Epub 2016 Feb 23.

PMID:
26902977
16.

Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.

Robinson AA, Wang J, Vardanyan S, Madden EK, Hebroni F, Udd KA, Spektor TM, Nosrati JD, Kitto AZ, Zahab M, Cheema S, Fors DH, Norberg A, Diehl J, Waterman GN, Swift RA, Crowley J, Berenson JR.

Eur J Haematol. 2016 Nov;97(5):439-444. doi: 10.1111/ejh.12748. Epub 2016 Mar 7.

PMID:
26872804
17.

Acute Response of PGC-1α and IGF-1 Isoforms to Maximal Eccentric Exercise in Skeletal Muscle of Postmenopausal Women.

Dieli-Conwright CM, Kiwata JL, Tuzon CT, Spektor TM, Sattler FR, Rice JC, Schroeder ET.

J Strength Cond Res. 2016 Apr;30(4):1161-70. doi: 10.1519/JSC.0000000000001171.

18.

Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women.

Dieli-Conwright CM, Spektor TM, Rice JC, Sattler FR, Schroeder ET.

J Strength Cond Res. 2012 May;26(5):1374-82. doi: 10.1519/JSC.0b013e318251083f.

PMID:
22395277
19.

The UBC9 E2 SUMO conjugating enzyme binds the PR-Set7 histone methyltransferase to facilitate target gene repression.

Spektor TM, Congdon LM, Veerappan CS, Rice JC.

PLoS One. 2011;6(7):e22785. doi: 10.1371/journal.pone.0022785. Epub 2011 Jul 29.

20.

PR-Set7-mediated monomethylation of histone H4 lysine 20 at specific genomic regions induces transcriptional repression.

Congdon LM, Houston SI, Veerappan CS, Spektor TM, Rice JC.

J Cell Biochem. 2010 Jun 1;110(3):609-19. doi: 10.1002/jcb.22570.

PMID:
20512922
21.

Hormone replacement therapy and messenger RNA expression of estrogen receptor coregulators after exercise in postmenopausal women.

Dieli-Conwright CM, Spektor TM, Rice JC, Sattler FR, Schroeder ET.

Med Sci Sports Exerc. 2010 Mar;42(3):422-9. doi: 10.1249/MSS.0b013e3181b7193f.

PMID:
20164697
22.

Identification and characterization of posttranslational modification-specific binding proteins in vivo by mammalian tethered catalysis.

Spektor TM, Rice JC.

Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14808-13. doi: 10.1073/pnas.0907799106. Epub 2009 Aug 18.

23.

Influence of hormone replacement therapy on eccentric exercise induced myogenic gene expression in postmenopausal women.

Dieli-Conwright CM, Spektor TM, Rice JC, Sattler FR, Schroeder ET.

J Appl Physiol (1985). 2009 Nov;107(5):1381-8. doi: 10.1152/japplphysiol.00590.2009. Epub 2009 Aug 20.

24.

Hormone therapy attenuates exercise-induced skeletal muscle damage in postmenopausal women.

Dieli-Conwright CM, Spektor TM, Rice JC, Sattler FR, Schroeder ET.

J Appl Physiol (1985). 2009 Sep;107(3):853-8. doi: 10.1152/japplphysiol.00404.2009. Epub 2009 Jul 2. Erratum in: J Appl Physiol. 2010 Sep;109(3):942. Sattler, F R [added].

25.

Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells.

Dieli-Conwright CM, Spektor TM, Rice JC, Todd Schroeder E.

Acta Physiol (Oxf). 2009 Nov;197(3):187-96. doi: 10.1111/j.1748-1716.2009.01997.x. Epub 2009 May 6.

PMID:
19432593
26.

Ring around the genes.

Spektor TM, Rice JC.

Nat Cell Biol. 2007 Dec;9(12):1343-4.

PMID:
18059356

Supplemental Content

Loading ...
Support Center